Literature DB >> 26975032

The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China.

Sarah Lewington1, Ben Lacey1, Robert Clarke1, Yu Guo2, Xiang Ling Kong1, Ling Yang1, Yiping Chen1, Zheng Bian2, Junshi Chen3, Jinhuai Meng4, Youping Xiong5, Tianyou He6, Zengchang Pang7, Shuo Zhang8, Rory Collins1, Richard Peto1, Liming Li9, Zhengming Chen1.   

Abstract

IMPORTANCE: Hypertension is a leading cause of premature death in China, but limited evidence is available on the prevalence and management of hypertension and its effect on mortality from cardiovascular disease (CVD).
OBJECTIVES: To examine the prevalence, diagnosis, treatment, and control of hypertension and to assess the CVD mortality attributable to hypertension in China. DESIGN, SETTING AND PARTICIPANTS: This prospective cohort study (China Kadoorie Biobank Study) recruited 500 223 adults, aged 35 to 74 years, from the general population in China. Blood pressure (BP) measurements were recorded as part of the baseline survey from June 25, 2004, to August 5, 2009, and 7028 deaths due to CVD were recorded before January 1, 2014 (mean duration of follow-up: 7.2 years). Data were analyzed from June 9, 2014, to July 17, 2015. EXPOSURES: Prevalence and diagnosis of hypertension (systolic BP ≥140 mm Hg, diastolic BP ≥90 mm Hg, or receiving treatment for hypertension) and treatment and control rates overall and in various population subgroups. MAIN OUTCOMES AND MEASURES: Cox regression analysis yielded age- and sex-specific rate ratios for deaths due to CVD comparing participants with and without uncontrolled hypertension, which were used to estimate the number of CVD deaths attributable to hypertension.
RESULTS: The cohort included 205 167 men (41.0%) and 295 056 women (59.0%) with a mean (SD) age of 52 (10) years for both sexes. Overall, 32.5% of participants had hypertension; the prevalence increased with age (from 12.6% at 35-39 years of age to 58.4% at 70-74 years of age) and varied substantially by region (range, 22.7%-40.7%). Of those with hypertension, 30.5% had received a diagnosis from a physician; of those with a diagnosis of hypertension, 46.4% were being treated; and of those treated, 29.6% had their hypertension controlled (ie, systolic BP <140 mm Hg; diastolic BP <90 mm Hg), resulting in an overall control rate of 4.2%. Even among patients with hypertension and prior CVD, only 13.0% had their hypertension controlled. Uncontrolled hypertension was associated with relative risks for CVD mortality of 4.1 (95% CI, 3.7-4.6), 2.6 (95% CI, 2.4-2.9) and 1.9 (95% CI, 1.8-2.0) at ages 35 to 59, 60 to 69, and 70 to 79 years, respectively, and accounted for about one-third of deaths due to CVD (approximately 750 000) at 35 to 79 years of age in 2010. CONCLUSIONS AND RELEVANCE: About one-third of Chinese adults in this national cohort population had hypertension. The levels of diagnosis, treatment, and control were much lower than in Western populations, and were associated with significant excess mortality.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26975032     DOI: 10.1001/jamainternmed.2016.0190

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  122 in total

Review 1.  The Impact of Chromium Supplementation on Blood Pressure: A Systematic Review and Dose-Response Meta‑Analysis of Randomized‑Controlled Trials.

Authors:  Abolfazl Lari; Somaye Fatahi; Mohammad Hassan Sohouli; Farzad Shidfar
Journal:  High Blood Press Cardiovasc Prev       Date:  2021-06-03

Review 2.  Precision medicine in cardiology.

Authors:  Elliott M Antman; Joseph Loscalzo
Journal:  Nat Rev Cardiol       Date:  2016-06-30       Impact factor: 32.419

3.  Hypertension prevalence, awareness, treatment, and control in northeast China: a population-based cross-sectional survey.

Authors:  Fu-Liang Zhang; Zhen-Ni Guo; Ying-Qi Xing; Yan-Hua Wu; Hao-Yuan Liu; Yi Yang
Journal:  J Hum Hypertens       Date:  2017-11-27       Impact factor: 3.012

4.  [Effects of CYP2D6*10 on plasma trough concentration of metoprolol in patients with coronary artery disease].

Authors:  Qian Zhu; Weihua Lai; Liwen Li; Hanping Li; Shilong Zhong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

5.  SNPs rs10224002 in PRKAG2 may disturb gene expression and consequently affect hypertension.

Authors:  Xingbo Mo; Huan Zhang; Zhengyuan Zhou; Zhengbao Zhu; Xinfeng HuangFu; Tan Xu; Aili Wang; Zhirong Guo; Yonghong Zhang
Journal:  Mol Biol Rep       Date:  2019-01-28       Impact factor: 2.316

6.  Bioequivalence and Pharmacokinetics of Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablet versus Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet: An Open-Label, Randomized, Two-Sequence Crossover Study in Healthy Chinese Subjects.

Authors:  Chaoying Hu; Xiao Hu; Chunhua Wang; Zirun Zhao; Dan Gao; Xiaoping Chen; Dongli Zhou; Yue Huang; Lin Li; Lan Zhang
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

7.  The prevalence of depressive symptoms among older patients with hypertension in rural China.

Authors:  Jiang Xue; Shulin Chen; Hillary R Bogner; Wan Tang; Lydia Li; Yeates Conwell
Journal:  Int J Geriatr Psychiatry       Date:  2016-11-28       Impact factor: 3.485

Review 8.  Associations among NPPA gene polymorphisms, serum ANP levels, and hypertension in the Chinese Han population.

Authors:  Huan Zhang; Xingbo Mo; Zhengyuan Zhou; Zhengbao Zhu; Xinfeng HuangFu; Tan Xu; Aili Wang; Zhirong Guo; Yonghong Zhang
Journal:  J Hum Hypertens       Date:  2019-07-24       Impact factor: 3.012

9.  Health-related quality of life among rural men and women with hypertension: assessment by the EQ-5D-5L in Jiangsu, China.

Authors:  Zhuoru Liang; Tiantian Zhang; Tengfei Lin; Lishun Liu; Binyan Wang; Alex Z Fu; Xiaobin Wang; Xiping Xu; Nan Luo; Jie Jiang
Journal:  Qual Life Res       Date:  2019-03-04       Impact factor: 4.147

10.  Deaths from total and premature cardiovascular disease associated with high normal blood pressure and hypertension in rural Chinese men and elderly people.

Authors:  Leilei Liu; Yu Liu; Yongcheng Ren; Yang Zhao; Pei Qin; Dechen Liu; Xu Chen; Cheng Cheng; Feiyan Liu; Chunmei Guo; Qionggui Zhou; Quanman Li; Gang Tian; Minghui Han; Ranran Qie; Xiaoyan Wu; Shengbing Huang; Xinping Luo; Ruirong Cheng; Dongsheng Hu; Jian Wang; Ming Zhang
Journal:  J Hum Hypertens       Date:  2020-07-20       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.